Kinnate Biopharma Inc. to Participate in the 2022 Piper Sandler Heartland Summit

Posted: September 16, 2022 at 2:43 am

SAN FRANCISCO and SAN DIEGO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that its chief executive officer, Nima Farzan, will participate in the Piper Sandler Heartland Summit as part of the panel “Healthcare Politics: FDA Proposals from Optimus, to ORBIS to RTOR and CONFIRM – How Might These Proposals Impact Oncology Drug Development and Implications?” on Thursday, September 22, 2022 at 11:30 a.m. C.T.

Continued here:
Kinnate Biopharma Inc. to Participate in the 2022 Piper Sandler Heartland Summit

Related Posts